ABL Bio Inc. (KOSDAQ: 298380)
South Korea
· Delayed Price · Currency is KRW
40,500
+5,400 (15.38%)
Oct 11, 2024, 9:00 AM KST
ABL Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 32,955 | 65,547 | 67,301 | 5,332 |
Other Revenue | 0 | 0 | -0 | 0 |
Revenue | 32,955 | 65,547 | 67,301 | 5,332 |
Revenue Growth (YoY) | -66.11% | -2.61% | 1162.19% | - |
Cost of Revenue | 62.74 | 46.25 | 83.76 | 47.98 |
Gross Profit | 32,892 | 65,501 | 67,217 | 5,284 |
Selling, General & Admin | 15,526 | 13,493 | 15,569 | 13,962 |
Research & Development | 55,789 | 52,035 | 48,416 | 41,034 |
Operating Expenses | 73,838 | 68,118 | 66,309 | 56,472 |
Operating Income | -40,946 | -2,617 | 908 | -51,188 |
Interest Expense | -850.95 | -2,151 | -1,326 | -41.98 |
Interest & Investment Income | 1,123 | 1,294 | 233.75 | 99.72 |
Currency Exchange Gain (Loss) | 448.69 | 734.04 | 1,761 | 864.43 |
Other Non Operating Income (Expenses) | -679.52 | -1,037 | 2,176 | 47.62 |
EBT Excluding Unusual Items | -40,905 | -3,776 | 3,753 | -50,218 |
Gain (Loss) on Sale of Investments | 904.99 | 1,132 | -592.13 | 6,666 |
Gain (Loss) on Sale of Assets | -2.64 | -2.64 | 48 | -5.83 |
Pretax Income | -40,003 | -2,647 | 3,209 | -43,558 |
Net Income | -40,003 | -2,647 | 3,209 | -43,558 |
Net Income to Common | -40,003 | -2,647 | 3,209 | -43,558 |
Shares Outstanding (Basic) | 48 | 48 | 48 | 47 |
Shares Outstanding (Diluted) | 48 | 48 | 48 | 47 |
Shares Change (YoY) | 0.29% | 0.58% | 1.27% | - |
EPS (Basic) | -835.12 | -55.32 | 67.46 | -927.36 |
EPS (Diluted) | -835.12 | -55.32 | 67.46 | -927.36 |
Free Cash Flow | -73,486 | -34,102 | 70,076 | -41,850 |
Free Cash Flow Per Share | -1534.13 | -712.77 | 1473.24 | -890.99 |
Gross Margin | 99.81% | 99.93% | 99.88% | 99.10% |
Operating Margin | -124.25% | -3.99% | 1.35% | -959.99% |
Profit Margin | -121.39% | -4.04% | 4.77% | -816.91% |
Free Cash Flow Margin | -222.99% | -52.03% | 104.12% | -784.87% |
EBITDA | -38,424 | -27.32 | 3,233 | -49,029 |
EBITDA Margin | -116.60% | -0.04% | 4.80% | - |
D&A For EBITDA | 2,522 | 2,590 | 2,325 | 2,158 |
EBIT | -40,946 | -2,617 | 908 | -51,188 |
EBIT Margin | -124.25% | -3.99% | 1.35% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.